Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
$43.11
+0.3%
$61.64
$37.06
▼
$95.49
$6.09B1.342.27 million shs2.42 million shs
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
$6.70
+7.0%
$8.51
$1.95
▼
$12.43
$7.13B0.1719.87 million shs15.79 million shs
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
$97.81
+1.0%
$79.26
$19.04
▼
$112.79
$6.40B2.021.12 million shs744,856 shs
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
$14.10
-1.0%
$22.80
$12.61
▼
$28.23
$1.54B1.81.75 million shs2.79 million shs
10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
-2.76%-12.27%-23.09%-51.92%+7.07%
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
+4.68%-7.12%-31.81%-23.00%+208.37%
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
-3.90%-10.42%+12.89%+141.58%+388.15%
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
-3.33%-10.33%-41.69%-48.76%+11.34%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
$43.11
+0.3%
$61.64
$37.06
▼
$95.49
$6.09B1.342.27 million shs2.42 million shs
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
$6.70
+7.0%
$8.51
$1.95
▼
$12.43
$7.13B0.1719.87 million shs15.79 million shs
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
$97.81
+1.0%
$79.26
$19.04
▼
$112.79
$6.40B2.021.12 million shs744,856 shs
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
$14.10
-1.0%
$22.80
$12.61
▼
$28.23
$1.54B1.81.75 million shs2.79 million shs
10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
-2.76%-12.27%-23.09%-51.92%+7.07%
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
+4.68%-7.12%-31.81%-23.00%+208.37%
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
-3.90%-10.42%+12.89%+141.58%+388.15%
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
-3.33%-10.33%-41.69%-48.76%+11.34%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
2.73
Moderate Buy$98.71128.98% Upside
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
2.71
Moderate Buy$16.00138.81% Upside
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
2.63
Moderate Buy$109.0011.44% Upside
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
2.87
Moderate Buy$34.43144.17% Upside

Current Analyst Ratings Breakdown

Latest NRIX, KOD, ARWR, and IBRX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/17/2026
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
Lower Price TargetBuy$108.00 ➝ $105.00
11/13/2026
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
Reiterated RatingSell (D-)
11/13/2026
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
Reiterated RatingOutperform$100.00
11/13/2026
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
Lower Price TargetBuy$104.00 ➝ $96.00
11/13/2026
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
Boost Price TargetBuy$120.00 ➝ $150.00
11/4/2026
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
Lower Price TargetHold ➝ Overweight$25.00 ➝ $20.00
10/16/2026
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
Boost Price TargetBuy$34.00 ➝ $36.00
10/15/2026
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
Reiterated RatingSell (D-)
10/15/2026
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
Initiated CoverageBuy$63.00 ➝ $109.00
10/15/2026
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
Reiterated RatingBuy$115.00
10/15/2026
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
Reiterated RatingBuy$120.00
(Data available from 11/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
$450.82M13.52N/AN/A$0.36 per share119.75
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
$113.29M62.92N/AN/A($1.08) per share-6.20
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
N/AN/AN/AN/A$0.19 per shareN/A
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
$83.98M18.34N/AN/A$5.29 per share2.67
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
-$724.21M-$5.11N/AN/AN/A-160.64%-172.62%-37.51%2/4/2027 (Estimated)
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
-$351.40M-$1.08N/AN/AN/A-607.79%N/A-54.83%N/A
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
-$229.97M-$4.08N/AN/AN/AN/A-287.64%-87.83%N/A
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
-$264.46M$2.316.10N/AN/A42.01%49.34%38.61%1/27/2027 (Estimated)

Latest NRIX, KOD, ARWR, and IBRX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/12/2026Q3 2026
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
-$1.06-$1.05+$0.01-$1.05N/AN/A
10/13/2026Q3 2026
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
-$0.6009$4.73+$5.3309$4.73$24.35 million$673.06 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
N/AN/AN/AN/AN/A
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
N/AN/AN/AN/AN/A
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
N/AN/AN/AN/AN/A
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
16.61
4.14
4.11
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
N/A
4.27
4.27
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
N/A
1.70
1.70
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
N/A
8.44
8.44

Institutional Ownership

CompanyInstitutional Ownership
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
62.61%
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
8.58%
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
89.06%
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
N/A

Insider Ownership

CompanyInsider Ownership
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
3.60%
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
66.10%
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
44.40%
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
6.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
1,062141.37 million135.79 millionOptionable
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
6911.06 billion360.64 millionOptionable
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
12465.40 million34.94 millionOptionable
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
357109.25 million101.93 millionOptionable

Recent News About These Companies

Why Nurix Therapeutics (NRIX) stock is down today

New MarketBeat Followers Over Time

Media Sentiment Over Time

Arrowhead Pharmaceuticals stock logo

Arrowhead Pharmaceuticals NASDAQ:ARWR

$43.11 +0.12 (+0.28%)
Closing price 04:00 PM Eastern
Extended Trading
$43.12 +0.02 (+0.03%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.

ImmunityBio stock logo

ImmunityBio NASDAQ:IBRX

$6.70 +0.44 (+7.03%)
Closing price 04:00 PM Eastern
Extended Trading
$6.75 +0.05 (+0.75%)
As of 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.

Kodiak Sciences stock logo

Kodiak Sciences NASDAQ:KOD

$97.81 +1.01 (+1.04%)
Closing price 04:00 PM Eastern
Extended Trading
$97.76 -0.05 (-0.05%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.

Nurix Therapeutics stock logo

Nurix Therapeutics NASDAQ:NRIX

$14.10 -0.14 (-0.98%)
Closing price 04:00 PM Eastern
Extended Trading
$14.26 +0.16 (+1.13%)
As of 07:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.